SOD1 and amyotrophic lateral sclerosis: In the 6-month phase III trial of tofersen in symptomatic mutant SOD1 ALS patients, serum neurofilament levels were lowered by 60%, suggesting a substantial slowing of the neurodegenerative disease process.